55687-30-4

Basic information

• Product Name: 2(1H)-Quinoxalinone, 7-methoxy-
• Synonyms: 2(1H)-Quinoxalinone, 7-methoxy-;7-Methoxyquinoxalin-2(1H)-one;7-methoxyquinoxalin-2-ol;7-methoxy-2(1H)-quinoxalinone
• CAS NO: 55687-30-4
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Mol File: 55687-30-4.mol
• Article Data: 18

Chemical Properties

• Melting Point: 235-236 °C
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.55±0.70(Predicted)
• CAS DataBase Reference: 2(1H)-Quinoxalinone, 7-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone, 7-methoxy-(55687-30-4)
• EPA Substance Registry System: 2(1H)-Quinoxalinone, 7-methoxy-(55687-30-4)

Safety Data

• Hazardous Substances Data: 55687-30-4(Hazardous Substances Data)

Usage

General Description

2(1H)-Quinoxalinone, 7-methoxy- is a chemical compound with the molecular formula C10H9N2O2. It is a derivative of the quinoxalinone family, which is known for its various biological activities including antifungal, antibacterial, antiviral, anticancer, and antidepressant properties. The addition of a methoxy group to the seventh position of the quinoxalinone ring may impart specific pharmacological activities to this compound. It is of interest in the pharmaceutical industry for its potential therapeutic applications, and research is ongoing to explore its pharmacological properties and potential medicinal uses.

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 4685-47-6 3,4-dimethylanisole 
• 96-96-8 4-methoxy-2-nitroaniline 
• 118807-88-8 2-((4-methoxy-2-nitrophenyl)amino)acetonitrile 
• 55687-28-0 (4-methoxy-2-nitrophenyl)glycine 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 59548-39-9 4-methoxyphenylene-1,2-diamine dihydrochloride 
• 1033312-27-4 [(4-methoxy-2-nitrophenyl)imino]ethyl acetate 
• 118807-82-2 (4-methoxy-2-nitro-phenylamino)-acetic acid ethyl ester 
• 298-12-4 Glyoxilic acid 
• 55687-29-1 7-methoxy-3,4-dihydroquinoxalin-2(1H)-one 
• 577-72-0 4-methoxy-3-nitroaniline 

Downstream Products

• 1598416-94-4 1-(2-(4-(4-fluoro-3-nitrobenzylamino)piperidin-1-yl)ethyl)-7-methoxyquinoxalin-2(1H)-one 
• 1598417-00-5 7-methoxy-1-(2-(4-(4-methyl-3-nitrobenzylamino)piperidin-1-yl)ethyl)quinoxalin-2(1H)-one 
• 1598417-01-6 1-(2-(7-methoxyquinoxalin-2-yloxy)ethyl)-N-(4-methyl-3-nitrobenzyl)piperidin-4-amine 
• 1598417-04-9 1-(2-(4-(4-bromo-3-nitrobenzylamino)piperidin-1-yl)ethyl)-7-methoxyquinoxalin-2(1H)-one 
• 1598417-05-0 7-methoxy-1-(2-(4-(3-methyl-4-nitrobenzylamino)piperidin-1-yl)ethyl)quinoxalin-2(1H)-one 
• 55686-93-6 2-chloro-7-methoxyquinoxaline 

Relevant articles and documents

Copper-Catalyzed Divergent C-H Functionalization Reaction of Quinoxalin-2(1H)-ones and Alkynes Controlled by N1-Substituents for the Synthesis of (Z)-Enaminones and Furo[2,3-b]quinoxalines

With control by N1-substituents, the switchable divergent C-H functionalization reaction of quinoxalin-2(1H)-ones is achieved for the synthesis of (Z)-enaminones and furo[2,3-b]quinoxalines using the combination of a copper catalyst and an oxidant. This new protocol features mild reaction conditions, readily available materials, and a broad substrate scope. Gram-scale and mechanistic studies were also investigated. Furthermore, the desired products exhibited excellent antitumor activity against A549, HepG-2, MCF-7, and HeLa cells, which were tested by MTT assay.

Photocatalytic Giese Addition of 1,4-Dihydroquinoxalin-2-ones to Electron-Poor Alkenes Using Visible Light

The visible-light photoredox-catalyzed coupling of 1,4-dihydroquinoxalin-2-ones and Michael acceptors was achieved using Ru(bpy)3Cl2 as the photocatalyst and (PhO)2PO2H as an additive. The optimized reaction conditions provide a good yield for the radical conjugate addition products (44 examples) with a wide range of structurally different Michael acceptors. A gram scale reaction using sunlight irradiation is also described. Furthermore, several transformations were carried out with the Giese addition products.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.